BIOPHARMA
ByCan Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients Served Amid Gene Therapy Market Reality Check
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
